Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)

NCT07565324 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

HER-2 Positive Breast Cancer

Interventions

DRUG: Lipo-Dox®
DRUG: Cyclophosphamide
DRUG: Trastuzumab (Herceptin)
DRUG: Pertuzumab

Sponsor

National Taiwan University Hospital

Collaborators

[object Object]